Figure 4 from Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia
Year: 2025
Type: other
Abstract: Antileukemic effects of the velcrin–Aza combination. A and B, Cell viability of HEL (A) or U937 (B) cells treated with DMSO (vehicle control) or with increasing concentrations of BAY 2666605 (BAY), Aza, or the combination of BAY 2666605 with Aza as measured by WST-1 cell viability assay. Data are presented as the means ± SEM of three independent experiments, each conducted in triplicate, and are expressed as percent cell viability relative to vehicle control (DMSO)–treated cells. IC50 values for the indicated cell lines were calculated by fitting a nonlinear regression analysis using the “log (inhibitor) vs. response - three parameters” function in GraphPad Prism software (v.10). CI was calculated using Compusyn software, in which CI < 1 is synergistic, CI > 1 is antagonistic, and CI = 1 is additive. C and D, Clonogenic capability of (C) HEL or (D) U937 cells plated in a methylcellulose culture assay system in the presence of BAY 2666605, Aza, or the combination of BAY 2666605 with Aza, relative to vehicle control (DMSO; indicated by the dotted line) at the indicated concentrations. The percent of leukemic colony formation (CFU-L) is shown relative to vehicle control (DMSO)–treated cells and represents mean ± SEM of four independent experiments. Each dot represents an independent experiment. Statistical significance was determined using a one-way ANOVA, followed by a Tukey multiple comparisons test to correct for pairwise comparisons; ns, not significant; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. BAY, BAY 2666605.
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416300037
Cites:
Cited by:
Related to: